Suppr超能文献

年龄和性别依赖性对钛椎体增强植入物联合骨水泥固定后椎体骨折发生率的影响:与单纯骨水泥固定的比较研究。

Age- and gender-dependent impact of titanium vertebral augmentation implants combined with cementing on subsequent vertebral fracture incidence: A comparative study with cementing alone.

机构信息

Department of Neurosurgery, Taipei Medical University Hospital, Taipei, Taiwan.

Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.

出版信息

Eur Spine J. 2024 Dec;33(12):4513-4520. doi: 10.1007/s00586-024-08504-2. Epub 2024 Oct 4.

Abstract

PURPOSE

To compare vertebroplasty (VP) and kyphoplasty (KP) with a titanium implantable vertebral augmentation device (TIVAD) in symptomatic subsequent vertebral compression fracture (SVCF) incidence among osteoporotic vertebral compression fracture (OVCF) patients stratified by age and sex.

METHODS

This retrospective cohort study involved OVCF patients aged ≥ 50, who underwent KP with TIVAD or VP in our hospital from 2014 to 2019. Subgroup analysis was conducted to evaluate the efficacy of KP with TIVAD and VP in patients stratified by age and sex.

RESULTS

The study included 472 patients (VP group: 303; TIVAD group: 169). SVCF incidence rates were 15.2% for VP group and 14.8% for TIVAD group (P = 0.87). In subgroup analysis, TIVAD group showed significantly lower SVCF incidence than VP group in women aged 50-70 (2.1% vs 14.3%; P = 0.03) and had significantly higher SVCF incidence than VP group in women aged > 70 (24.2% vs 13.1%; P = 0.02). In men, adjacent SVCF incidence was significantly lower in TIVAD group than VP group (0% vs 14.1%; P = 0.03).

CONCLUSION

Compared to VP, TIVAD is associated with lower symptomatic SVCF rate in men and younger women aged 50-70 but not in older women aged > 70. Age and gender may influence SVCF incidence.

LEVEL OF EVIDENCE

Diagnostic: individual cross-sectional studies with consistently applied reference standard and blinding.

摘要

目的

比较经皮椎体成形术(VP)和经皮椎体后凸成形术(KP)联合钛可扩张椎体成形装置(TIVAD)与年龄和性别分层的骨质疏松性椎体压缩骨折(OVCF)患者的症状性后续椎体压缩骨折(SVCF)发生率。

方法

本回顾性队列研究纳入了 2014 年至 2019 年在我院接受 KP 联合 TIVAD 或 VP 治疗的年龄≥50 岁的 OVCF 患者。进行亚组分析,以评估 TIVAD 和 VP 在按年龄和性别分层的患者中的疗效。

结果

研究共纳入 472 例患者(VP 组 303 例,TIVAD 组 169 例)。VP 组和 TIVAD 组的 SVCF 发生率分别为 15.2%和 14.8%(P=0.87)。在亚组分析中,TIVAD 组在 50-70 岁女性中的 SVCF 发生率明显低于 VP 组(2.1%比 14.3%;P=0.03),而在>70 岁女性中的 SVCF 发生率明显高于 VP 组(24.2%比 13.1%;P=0.02)。在男性中,TIVAD 组的相邻 SVCF 发生率明显低于 VP 组(0%比 14.1%;P=0.03)。

结论

与 VP 相比,TIVAD 与男性和 50-70 岁的年轻女性 SVCF 发生率较低相关,但与>70 岁的老年女性无关。年龄和性别可能会影响 SVCF 的发生率。

证据水平

诊断:具有一致应用参考标准和盲法的个体横断面研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验